Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SOM1311 is a repurposed small molecule pharmacological chaperone of phenylalanine hydroxylase (PAH) under development by SOM Biotech for the treatment of phenylketonuria (PKU), a rare congenital metabolic disorder characterized by the accumulation of phenylalanine due to deficient PAH activity. As a PAH agonist and modulator, SOM1311 aims to stabilize and enhance the function of mutant or misfolded PAH enzyme, thereby reducing toxic levels of phenylalanine in patients with PKU. The drug was identified using artificial intelligence-based screening technology (SOMAIPRO) and has shown promising preclinical data supporting advancement directly into Phase 2a proof-of-concept clinical trials[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SOM1311.